poisar

Stocks · News reference

TD Cowen Maintains Buy on Cardinal Health, Raises Price Target to $280

Benzinga Newsdesk

TD Cowen analyst Charles Rhyee maintains Cardinal Health (NYSE:CAH) with a Buy and raises the price target from $275 to $280.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CAH
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Sara Appino

    AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

    AbbVie and Bristol Myers Squibb are compared as pharmaceutical investment options for 2026. AbbVie is recommended as the better buy due to its successful immunology franchise with Skyrizi and Rinvoq driving growth, diversification into aesthetics and neuroscience, and having navigated its patent cliff challenges. Bristol Myers Squibb, while cheaper on valuation metrics and maintaining strong profit margins, faces revenue stagnation, legal uncertainties from a Celgene acquisition lawsuit, and is still working through its own portfolio transition challenges.

    ABBVBMYCELGRMCKCAH
  2. Na

    Is Nuveen ESG Mid-Cap Value ETF (NUMV) a Strong ETF Right Now?

    The article provides an analysis of the Nuveen ESG Mid-Cap Value ETF (NUMV), a smart beta ETF launched in 2016 with $442.53 million in assets. NUMV tracks the TIAA ESG USA Mid-Cap Value Index with a 0.31% expense ratio and has returned 11.92% year-to-date and 14.53% over the past year. The fund holds 89 companies with heaviest exposure to Financials (19.6%), Industrials, and Information Technology sectors. Alternative ESG ETFs like ESGV and ESGU are also mentioned as comparable options.

    NUMVCAHSTTSTTPGXLF
  3. Na

    BTSG Faces $200M IRA Hit but Efficiency May Protect Profitability

    BrightSpring Health Services' Home and Community Pharmacy segment experienced an 8% revenue decline to $540M in Q2, with the Inflation Reduction Act (IRA) accounting for approximately $50M of the impact. Despite a projected $200M revenue headwind in 2026 from IRA pricing changes, the company expects only a $15M EBITDA impact, demonstrating that operational efficiency gains from technology, automation, AI, and Lean initiatives are offsetting regulatory pressures. Peer companies Cardinal Health and CVS Health are similarly navigating IRA-driven revenue pressures while maintaining profitability through service agreements and operational improvements.

    BTSGBTSGUCAHCVS
  4. Na

    Can CAH Navigate IRA Pricing Changes Risk Without Margin Pressure?

    Cardinal Health expects fiscal 2027 IRA pricing changes to create similar revenue headwinds as 2026, but management aims to preserve compensation and maintain profitability through distribution agreements and operational efficiency. Peers BrightSpring and CVS Health also face IRA-related revenue pressure but are offsetting impacts through operational improvements and specialty pharmacy growth.

    CAHBTSGBTSGUCVS